| Literature DB >> 32253449 |
Qiurong Ruan1,2, Kun Yang3, Wenxia Wang4, Lingyu Jiang5, Jianxin Song6.
Abstract
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.Entities:
Year: 2020 PMID: 32253449 PMCID: PMC7131986 DOI: 10.1007/s00134-020-06028-z
Source DB: PubMed Journal: Intensive Care Med ISSN: 0342-4642 Impact factor: 17.440
Fig. 1a Age distribution of patients with confirmed COVID-19; b key laboratory parameters for the outcomes of patients with confirmed COVID-19; c interval from onset of symptom to death of patients with confirmed COVID-19; d summary of the cause of death of 68 died patients with confirmed COVID-19
Supplementary Table 1: Summary of clinical features and laboratory results of the patients with confirmed COVID-19
| Age, years | 67 (15-81) | 50 (44-81) | <0.001 | |
| Sex | ||||
| Male | 49 (72%) | 53 (65%) | ||
| Female | 19 (28%) | 29 (35%) | ||
| Comorbidities | 43 (63%) | 34 (41%) | 0.01 | |
| Hypertension | 29 (43%) | 23 (28%) | 0.07 | |
| Cardiovascular disease | 13 (19%) | 0 | <0.001 | |
| Diabetes | 12 (18%) | 13 (16%) | 0.88 | |
| Cerebrovascular disease | 7 (10%) | 5 (6%) | 0.49 | |
| Chronic obstructive pulmonary disease | 2 (3%) | 1 (1%) | 0.59 | |
| Chronic kidney disease | 2 (3%) | 0 | 0.20 | |
| Malignancy | 2 (3%) | 1 (1%) | 0.59 | |
| Chronic liver disease | 1 (1%) | 3 (4%) | 0.63 | |
| Connective tissue disease | 1 (1%) | 0 | 0.45 | |
| Fever | 59 (87%) | 68 (83%) | 0.67 | |
| Cough | 51 (75%) | 59 (72%) | 0.81 | |
| Sputum production | 29 (43%) | 25 (30%) | 0.17 | |
| Fatigue | 15 (22%) | 22 (27%) | 0.63 | |
| Myalgia | 9 (13%) | 10 (12%) | 1 | |
| Haemoptysis | 3 (4%) | 0 | 0.09 | |
| Dyspnea | 59 (87%) | 51 (62%) | 0.001 | |
| Respiratory failure | 58 (85%) | 13 (16%) | <0.001 | |
| ARDS | 55 (81%) | 7 (9%) | <0.001 | |
| Acute kidney injury | 21 (31%) | 2 (2%) | <0.001 | |
| Infection | 11 (16%) | 1 (1%) | 0.002 | |
| ICU admission | 30 (44%) | 11 (13%) | <0.001 | |
| High flow nasal cannula | 31 (46%) | 10 (12%) | <0.001 | |
| Non-invasive mechanical ventilation | 46 (68%) | 5 (6%) | <0.001 | |
| Invasive mechanical ventilation | 25 (37%) | 0 | <0.001 | |
| ECMO | 7 (10%) | 0 | 0.003 | |
| CRRT | 5 (7%) | 0 | 0.02 | |
| Prone position mechanical ventilation | 3 (4%) | 0 | 0.09 | |
| Antiviral treatment | 33 (49%) | 55 (67%) | 0.05 | |
| Antibiotic treatment | 63 (93%) | 80 (98%) | 0.66 | |
| Antifungal treatment | 12 (18%) | 5 (6%) | 0.04 | |
| Glucocorticoid treatment | 31 (46%) | 22 (27%) | 0.02 | |
| Time from onset of symptom to start of Glucocorticoid treatment, days | 11.7 (6.9) | 11.4 (4.4) | 0.89 | |
| Time from hospital admission to start of Glucocorticoid treatment, days | 1.5 (1.2) | 3.2 (2.7) | 0.01 | |
| Glucocorticoid treatment duration, days | 7.2 (6.7) | 7.0 (5.0) | 0.92 | |
| Supportive therapy | 45 (66%) | 18 (22%) | <0.001 | |
| Length of stay, days | 7.4 (5.5) | 12.3 (4.4) | <0.001 | |
| Time from onset of symptom to test, days | 11.6 (6.8) | 9.8 (4.3) | 0.07 | |
| White blood cell count, × 109/L | 3.50-9.50 | 10.62 (4.76) | 6.76 (3.49) | <0.001 |
| Lymphocyte count, × 109/L | 1.10-3.20 | 0.60 (0.32) | 1.42 (2.14) | <0.001 |
| Haemoglobin, g/L | 130.0-175.0 | 127.0 (16.7) | 127.6 (16.3) | 0.82 |
| Platelet count, × 109/L | 125.0-350.0 | 173.6 (67.7) | 222.1 (78.0) | <0.001 |
| Albumin, g/L | 35.0-52.0 | 28.8 (3.8) | 32.7 (3.8) | <0.001 |
| Alanine aminotransferase, U/L | 9.0-50.0 | 170.8 (991.6) | 48.68 (83.1) | 0.35 |
| Aspartate aminotransferase, U/L | 15.0-40.0 | 288.9 (1875.5) | 40.7 (57.8) | 0.31 |
| Total bilirubin, μmol/L | 0.0-26.0 | 18.1 (10.7) | 12.8 (6.8) | 0.001 |
| Blood urea nitrogen, mmol/L | 3.1-8.0 | 8.65 (4.5) | 5.11 (2.1) | <0.001 |
| Creatinine, umol/L | 59.0-104.0 | 91.2 (56.2) | 72.1 (22.2) | 0.02 |
| Creatine kinase, U/L | 50.0-310.0 | 319.4 (838.5) | 231.7 (862.3) | 0.56 |
| Lactate dehydrogenase, U/L | 120.0-250.0 | 905.8 (2619.1) | 297.9 (110.4) | 0.08 |
| Cardiac troponin, pg/mL | 2.0-28.0 | 30.3 (151.0) | 3.5 (6.2) | <0.001 |
| Myoglobin, ng/mL | 0.0-146.9 | 258.9 (307.6) | 77.7 (136.1) | <0.001 |
| C-reactive protein, mg/L | 0.0-5.0 | 126.6 (106.3) | 34.1 (54.5) | <0.001 |
| Interleukin-6, pg/mL | 0.0-7.0 | 11.4 (8.5) | 6.8 (3.61) | <0.001 |
| Serum ferritin, ng/mL | 21.8-274.7 | 1297.6 (1030.9) | 614.0 (752.2) | <0.001 |
Data are n (%), n/N (%), mean (SD), and median (IQR). When the data were normally distributed, continuous variables were then described using median and interquartile range (IQR) values.
ARDS = acute respiratory distress syndrome. ECMO = extracorporeal membrane oxygenation. ICU = intensive care unit. CRRT = continuous renal replacement therapy.